Cancer de l’ovaire : la rechute précoce

Bull Cancer. 2017 May:104 Suppl 1:S32-S38. doi: 10.1016/S0007-4551(17)30160-1.
[Article in French]

Abstract

EARLY RELAPSE: Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).

Keywords: Cancer de l’ovaire; Early relapse; Ovarian cancer; Rechute précoce.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / therapeutic use
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Gemcitabine
  • Humans
  • Neoplasm Recurrence, Local / drug therapy*
  • Ovarian Neoplasms / drug therapy*
  • Paclitaxel / therapeutic use
  • Topotecan / therapeutic use

Substances

  • Antineoplastic Agents
  • Deoxycytidine
  • Bevacizumab
  • Topotecan
  • Doxorubicin
  • Paclitaxel
  • Gemcitabine